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Abstract 
Background and aim: This paper is an official guideline of the European Society of 
Gastrointestinal Endoscopy (ESGE) and the European Society of Gastrointestinal and 
Abdominal Radiology (ESGAR). It addresses the clinical indications for the use of CT 
Colonography (CTC). 
Methods: A targeted literature search was performed to evaluate the evidence supporting 
the use of CTC. The Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) system was adopted to define the strength of recommendation and the 
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quality of evidence. 
Main recommendations:  
1) ESGE/ESGAR recommend CT colonography as the radiological examination of choice for 
the diagnosis of colorectal neoplasia.  ESGE/ESGAR do not recommend barium enema in 
this setting (strong recommendation; high quality evidence). 
2) ESGE/ESGAR recommend CT colonography, preferably the same or next day, if 
colonoscopy is incomplete. Consideration should be made to delaying CTC following 
endoscopic resections. In the case of obstructing colorectal cancer, pre-operative contrast-
enhanced CT colonography may also allow locating/staging malignant lesions. (strong 
recommendation, moderate quality evidence)  
3) ESGE/ESGAR recommend CT colonography as an alternative to colonoscopy for patients 
with symptoms suggestive of colorectal cancer (Recommendation: Strong; Evidence Level: 
High) 
4) ESGE/ESGAR recommend referral for endoscopic polypectomy in patients with at least 
one polyp ≥6 mm in diameter detected at CTC. CTC surveillance may be clinically 
considered if patients do not undergo polypectomy (Recommendation: Strong; Evidence 
Level: Moderate). 
5) ESGE/ESGAR do not recommend CT colonography (CTC) as a primary test for 
population screening or in subjects with a first-degree positive family history of CRC. 
However, it may be proposed as a CRC screening  test  on an individual basis providing the 
screenee is adequately informed about test characteristics, benefits and risks. 
(Recommendation: Weak; Evidence Level: Moderate). 
 
INTRODUCTION 
Colorectal cancer (CRC) is a major cause of morbidity and mortality (1, 2). CRC screening 
by faecal occult blood testing (FOBT) has been shown to reduce CRC mortality (3, 4), and  
is currently used in several European countries. Colonoscopy is highly effective for detecting 
advanced neoplasia, and endoscopic polypectomy reduces subsequent CRC-specific 
incidence and mortality (5). In Europe, colonoscopy is mainly used to investigate FOBT-
positive or symptomatic patients, or as preventive strategy in subjects with increased CRC 
risk (6).  
 
Computed Tomographic Colonography (CTC) is a minimally invasive imaging technique, 
highly accurate for detecting colorectal cancer (CRC) and adenomatous polyps. Technique 
is standardized (7), and CTC is easier to be performed than barium enema. Evidence-based 
data suggest that CTC is the natural replacement for barium enema and a complementary 
rather than an alternative examination to colonoscopy. However, the clinical scenarios for 
which CTC is indicated remain unclear. To address this uncertainty – twenty years after the 
first presentation of CTC in a radiological meeting (8) – the European Society of 
Gastrointestinal Endoscopy (ESGE) and the European Society of Gastrointestinal and 
Abdominal Radiology (ESGAR) decided to produce a common guideline regarding 
indications for CTC in clinical practice. 
 
METHODS 
The ESGE and ESGAR commissioned this guideline (chairs C.S. and A.L.) and invited the 
listed authors to participate to the development of the guideline. The key questions were 
prepared by the coordinating team (C.S. and A.L.) and then approved by the other members 
(see Appendix, available online). The coordinating team formed subgroups, each with its 
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own leader, and divided the key topics among these task forces. Each task force performed 
a systematic literature search to prepare evidence-based statements on their assigned key 
questions. Medline, EMBASE and other databases were searched including the following 
key words as minimum: ‘colon, cancer or malignancy or neoplasm, and CTC’. All articles 
investigating CTC in symptomatic or screening contexts were selected by inspecting the title 
and abstract. Hereditary colorectal syndromes were excluded. After further exploration of the 
content, each task-force summarised the included articles in a table of evidence (see 
Appendix, available online). All selected articles were graded on level of evidence and 
strength of recommendation according to the GRADE system (9, 10). The literature 
searches were updated to September 2013. Each individual task force prepared statements 
answering their assigned key questions, which were discussed subsequently and voted on 
during a face-to-face meeting of the whole group held October 1st, 2013. In May 2014, a 
draft prepared by the coordinating team was sent to all group members for comment. After 
agreeing a final version, the manuscript was reviewed by two experts selected by the ESGE 
and ESGAR Governing Boards and then submitted to the journals of respective 
organizations.  This guideline will be reviewed in 2019 or sooner if new and relevant 
evidence becomes available. Any updates to the guideline in the interim will be noted on the 
ESGE (http://www.esge.com/esge-guidelines.html) and ESGAR (http://www.esgar.org) 
websites. 
 
RECOMMENDATIONS AND STATEMENTS 
Evidence statements and recommendations are stated in italics, key evidence statements 
and recommendations are in bold. 
 
1. ESGE/ESGAR recommend CT colonography as the radiological examination of choice for 
the diagnosis of colorectal neoplasia. ESGE/ESGAR do not recommend barium enema in 
this setting (strong recommendation; high quality evidence). 
 
CTC can be considered the best radiological test for the diagnosis of colorectal cancer. 
Several randomised (11-13), multi-(14, 15) and single-centre trials (16-18), and meta-
analysis(19-26), showed that CTC accuracy for both CRC and  large/advanced polyps is 
similar to colonoscopy in symptomatic and asymptomatic patients and clearly superior to 
barium enema (11). In a recent randomised trial (SIGGAR)(11, 13) comparing CTC with CS 
and BE, the detection rate of colorectal cancer or large polyps was significantly higher in 
patients assigned to CTC than in those assigned to BE (7.3% vs 5.6%, p<0.039) and similar 
between CS and CTC (11% for both procedures). In a comparative study between CS and 
BE (27), sensitivity and specificity of barium enema were respectively 38% and 86% for 
polyps of any size. In another publication (28), using a 5 mm threshold, per-patient 
sensitivity and specificity were respectively 41% and 82%; at a threshold greater than 10 
mm, values were respectively 48% and 90%. In a meta-analysis comparing the performance 
of barium enema with CTC (29) for detection of colorectal polyps ≥6 mm in average- and 
high-risk patients, CTC was more specific and more sensitive than barium enema for large 
(≥10 mm) and small (6-9 mm) polyps in both per-patient and per-polyp analysis. In this 
study, CTC showed an incremental diagnostic yield in sensitivity of 12.0% for polyps ≥10 
mm and 30.1% for polyps between 6 and 9 mm and in specificity of 10.3% for polyps ≥10 
mm in per-patient analysis. Apart from better diagnostic performance, CTC is more tolerated 
and acceptable to patients and delivers a lower effective radiation dose than barium enema 
(30). 
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2. ESGE/ESGAR recommend CT colonography, preferably the same or next day, if 
colonoscopy is incomplete. Consideration should be made to delaying CTC following 
endoscopic resections. In the case of obstructing colorectal cancer, pre-operative contrast-
enhanced CT colonography may also allow locating/staging malignant lesions. (strong 
recommendation, moderate quality evidence) 
 
Incomplete colonoscopy 
Incomplete CC has been reported to occur in 10-15% of all colonoscopies (31, 32), and it 
has been associated with a higher risk of interval cancers in epidemiological studies(33). 
Incomplete colonoscopy may be worked up by repetition of colonoscopy or by radiological 
procedures. Repeating colonoscopy is likely to be considered when the reason of the 
previous failure was inadequate bowel preparation(34, 35). On the other hand, radiological 
referral appears most frequently indicated in the case of difficult anatomy or patient 
intolerance(35). Several studies  (36-46) have investigated CTC as a completion procedure 
following incomplete colonoscopy. These studies show high technical feasibility, a relatively 
high diagnostic yield, and an adequate PPV, especially at 10 mm threshold. However, no 
study exploited an independent reference standard for subjects with a negative CTC, so that 
the specificity of CTC in this setting is unknown. However, there is no apparent reason why 
the high accuracy shown by CTC in both asymptomatic and symptomatic settings, especially 
for large polyps or CRC, should not be extrapolated to those subjects with incomplete 
colonoscopy. For this reason, the superiority of CTC over barium enema recently shown in a 
large randomized study should favour CTC over barium enema when  colonoscopy was 
incomplete (11). 
CTC timing 
CTC after incomplete colonoscopy requires a different approach than primary CTC. In case 
of endoscopic biopsy, same-day CTC can be performed. An (ultra-) low dose pre-CTC scan 
of the abdomen and pelvis before insertion of the rectal tube may rule out extraluminal gas 
indicating a colonoscopic perforation. In detail, 2 (0.8% 95% CI 0.1-2.7) perforations were 
detected in 262  patients undergoing CTC after incomplete colonoscopy (47). In case of 
endoscopic resection (i.e. polypectomy/mucosectomy), it is prudent to consider an 
approximately 2 week-delay before performing CTC. There is little scientific evidence 
concerning the interval between endoscopic resection and subsequent CTC, thus each case 
should undergo a clinical discussion between the endoscopist and the radiologist. However, 
in a recent study on 65 CRC patients with severe luminal narrowing after incomplete 
colonoscopy with either polypectomy or biopsy sampling, no extraluminal gas was detected 
at CTC within 24 hours (48). Other evidence for the safety of radiologic imaging after 
endoscopic biopsy comes from barium enema studies, both experimental and clinical (49) 
(50-52). These studies concluded that in a non-diseased colon, barium enema could be 
performed immediately after endoscopic biopsy without any risk. In case of endoscopic 
resection barium enema could be performed without any risk after 6 days. 
Incomplete colonoscopy due to obstructing CRC 
Accurate preoperative assessment of the whole colon is required to exclude synchronous 
CRC. In a recent population-based study of 13,683 Dutch patients diagnosed with CRC, 
3.9% were diagnosed with synchronous CRC, and in 34% of these cases the two tumours 
were located in different surgical segments (53). These data were in line with those from a 
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previous French study (54), as well as from other series (55). Failure to detect synchronous 
cancer can increase morbidity, and one study has shown that intra-operative palpation can 
miss up to 69% synchronous malignancies (56, 57). Thus, pre-operative whole-colon 
assessment is needed. CTC appears to be an effective and safe choice when obstructing 
CRC prevents a complete endoscopic assessment or when caecal intubation fails for other 
reasons. A recent study including 286 CRC cases after failed colonoscopy showed CTC-
negative predictive values of 100% and 97% for synchronous cancer and advanced 
neoplasia in a pre-operative setting (58). This is in line with a previous systematic review, 
showing an equivalent sensitivity for established cancer between colonoscopy and CTC(22), 
as well as similar cohort studies (44, 59-63).  
 
3. ESGE/ESGAR recommend CT colonography as an alternative to colonoscopy for patients 
with symptoms suggestive of colorectal cancer (Recommendation: Strong; Evidence Level: 
High) 
Patients with abdominal symptoms suggestive of CRC require detailed investigation, since 
neither clinical examination nor faecal testing reliably excludes CRC(64). The ideal test 
would also diagnose non-neoplastic conditions responsible for the symptoms (both within 
the colon and beyond it). Patient acceptability and safety are also important.  
 
Colorectal neoplasia 
In the SIGGAR trial no significant difference in the detection rates of large polyp (≥10mm) 
and CRC between CTC and CS was demonstrated(13). Furthermore, crude pooled 
sensitivity for CRC in the studies of symptomatic patients was 96% (169 CRC detected from 
176 (13). This is compatible with the 96.1% sensitivity for CRC reported in a meta-
analysis(22) that included both screening and symptomatic/high risk patients. When 
considering large (≥10mm) polyps alone, per-patient sensitivity ranged from 82% to 92% 
(19-21, 23, 25, 26) in five meta-analyses including screening, symptomatic, high-risk and 
FOBT positive patients. In the studies specifically investigating symptomatic patients, pooled 
sensitivity for large (≥10mm) lesions (excluding cancers) was 91.4% (53 of 58 patients). 
These data suggest that CTC and colonoscopy have similar sensitivity for detecting CRC 
and large polyps in symptomatic patients. Small (6-9mm) and diminutive (≤5mm) polyps are 
less relevant in symptomatic patients, since they cannot explain the patient’s symptoms. 
Nonetheless, the ability to opportunistically detect and remove early precursor lesions and 
perform patho-histologic analysis of diagnosed CRC remains as a potential advantage of 
colonoscopy over CTC.  
 
Colorectal non-neoplastic pathology 
Abdominal symptoms may be due to non-neoplastic colonic conditions, for which both CTC 
and colonoscopy may be useful. Diverticulosis is more commonly demonstrated at CTC than 
colonoscopy(13, 65), although the relationship between it and symptoms is less clear. 
Colonoscopy is more sensitive for the detection of colitis and anal pathology (13); 
furthermore it offers the possibility of sampling tissue. 
Extracolonic findings 
CTC is an abdominal CT examination with the ability to detect extracolonic diseases. 
Despite these lesions may occasionally explain the symptoms, incidental findings that 
ultimately prove unimportant may nonetheless provoke additional tests that are 
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inconvenient, costly and even harmful. Few studies of extracolonic findings focus specifically 
on symptomatic patients, in whom there is a higher prevalence of significant abnormality. 
The two largest series of screening(66) and symptomatic(11, 13)  patients reported a 0.35% 
and 1.9% rate of extracolonic malignancy respectively. Importantly, in the paired SIGGAR 
trials, at three-year follow-up there was no significant difference in rates of extracolonic 
malignancy between the two arms of each individual trial, although all arms were 
significantly above rates expected for the general population. The latter observation may be 
explained by subsequent use of CT to investigate persistent symptoms in patients 
randomised to colonoscopy or barium enema, although this remains unproven.  
4. ESGE/ESGAR do not recommend CT colonography (CTC) as a primary test for 
population screening or in subjects with a first-degree positive family history of CRC. 
However, it may be proposed as a CRC screening  test  on an individual basis providing the 
screenee is adequately informed about test characteristics, benefits and risks. 
(Recommendation: Weak; Evidence Level: Moderate).  
 
CTC Accuracy 
To date, only guaiac FOBT (gFOBT) and sigmoidoscopy have shown to reduce CRC 
mortality by 16% and 22-31% respectively (67-69). CTC has not been subject to randomized 
trials with CRC incidence or mortality as endpoints. Therefore, CTC accuracy is used as a 
surrogate end-point for CTC efficacy in a screening setting.  
CTC accuracy in average-risk screening populations has been investigated by a recent 
meta-analysis (24) which estimated per-patient sensitivity at 88% for advanced neoplasia 
≥10mm. One further primary study published after this review, showed similar results(16). In 
six screening studies, none of the 12 CRCs present were missed by CTC in average risk 
subjects (14, 16-18, 70-72). Subjects with a positive family history CRC or adenomas should 
be considered at high risk (73). One recent cohort study showed a 89% CTC sensitivity for 
advanced neoplasia >10 mm in this setting(74). 
Attendance and yield of CTC in screening 
The efficacy of a screening program does not only depend on the diagnostic accuracy of the 
screening test that is used, but also depends on participation. This is illustrated by the 
results of a large population-based randomised screening trial performed in the Netherlands 
reporting participation rates for colonoscopy and CTC of 22 % and 34% and detection rates 
for advanced neoplasia of 8.7 and 6.1 persons per 100 participants, respectively(12). 
Despite the higher sensitivity of colonoscopy and the fact that CTC participants were only 
referred to colonoscopy if they had lesions ≥10 mm detected by CTC, the number of invitees 
per 100 invitees found to have advanced neoplasia was similar between both screening 
modalities, namely 1.9 versus 2.1 per 100 invitees (12). The poorer sensitivity of CTC 
compared to colonoscopy was countered by its approximately 1.5 times higher participation 
rate. In case of serrated adenomas the diagnostic yield of colonoscopy was 5-time higher 
than CTC. This is of particular importance, since approximately 10-20% of CRC develops 
from serrated pathway(75). The diagnostic yield of CTC screening per 100 invitees would 
appear significantly higher than the yield of first round gFOBT, but similar to the yield of first 
round flexible sigmoidoscopy screening (2.2 per 100 invitees) and FIT screening (2.0 per 
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100 invitees when using a cut-off of 50 ngHb/ml)(76). One should however bear in mind that 
FOBT/FIT screening is repeated at 2-year intervals, whereas CTC and endoscopic 
screening are usually recommended at 5-10 year intervals.  
Acceptability of CTC screening 
A recent meta-analysis included articles on preferences and differences in burden for both 
average and high risk subjects who had undergone CTC as well as colonoscopy(77) 
(tandem design). Amongst the included studies, 3573 patients reported a preference for 
CTC, 927 subjects showed a preference for colonoscopy and 1116 showed no difference in 
preference. Almost half of the non-participants in a Dutch population-based screening trial 
made an informed decision on participation, as they were provided with adequate knowledge 
of CRC and CRC screening, and a positive attitude towards screening but nevertheless 
declined participation, suggesting that additional barriers to participation were present(78). 
Most declined screening by colonoscopy and CTC for similar reasons(79). However, 
colonoscopy invitees who declined most often mentioned ‘unpleasantness of the 
examination’ as their prime reason, while for CTC ‘no time/too much effort’ and ‘lack of 
symptoms’ were most cited. The last finding is consistent with the findings of the study of Ho 
et al, in which 38% did not participate in CTC screening because of procrastination and 12% 
because they were too busy(80).  As indicated above, most previous screening studies 
comparing perceived acceptability and burden of both techniques using a tandem design, 
showed a significant preference for CTC, with 46% to 95% of participants preferring CTC for 
future investigation(17, 81, 82). A recent Netherlands study performed within a population-
based screening trial showed that colonoscopy invitees expected the screening procedure 
and bowel preparation to be more burdensome than CTC invitees(83). CTC participants in 
the Dutch study however found their screening procedure slightly more burdensome than 
colonoscopy participants. Colonoscopy participants gave higher burden scores to drinking 
the bowel preparation, while CTC participants gave higher burden scores to related bowel 
movements (i.e. diarrhoea and bowel cramps). Although these differences were statistically 
significant, they were mostly small and thus the clinical relevance is limited for a clinical 
population, but more significant for a primary screening population. This is illustrated by the 
fact that intended participation in a subsequent screening round exceeded 90% for both 
colonoscopy and CTC.  
 
Safety of CTC screening 
Adverse events 
The risk of major adverse events due to the CTC examination itself (including the bowel 
preparation) is low and presumed lower than for colonoscopy(13, 84). Adverse events of 
CTC screening, however, should include events related to the entire episode, also including 
those related to any colonoscopy required to investigate CTC findings (e.g. post-
polypectomy bleeding). In a randomized trial comparing CTC with colonoscopy screening, 
serious adverse events were comparable for both procedures, (0.2% for CTC; 0.3% for 
colonoscopy)(12). These rates are similar to adverse events observed in randomized trials 
of FOBT and flexible sigmoidoscopy screening, respectively(85). In a recent meta-
analysis(86) on 103,399 asymptomatic and symptomatic patients, CTC perforation rate was 
estimated to be 0.04 %, 19-fold higher in symptomatic than in screening subjects. The 
surgical rate was 0.008 % and no CTC-related deaths were reported 
Radiation risk in screening 
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Radiation exposure at CTC is associated with a risk of cancer induction. This risk is relevant 
for all individuals but especially so in screening where benefit should clearly outweigh 
potential harm. The risk associated with ionising radiation at a single CTC is very small and 
has been estimated as an absolute lifetime cancer risk of 0.14% for a 50 year old and 0.07% 
for a 70 year old, and can be reduced substantially with protocol optimisation(87). Another 
study reported a less than 0.2% increase of the lifetime cancer risk in individuals undergoing 
CTC screening every 5 years between the ages of 50 and 80 years(88). A study compared 
the anticipated cancer induced versus anticipated cancer prevented by CTC screening using 
the effective dose of a screening study (7 mSv for men and 8 mSv for women)(89). In that 
study the radiation related lifetime cancer risk for a single screening CTC was 0.06% for a 
50-year-old person and decreased with age. The corresponding calculated benefit-risk ratio 
for a 50-year-old person ranged from 24:1 to 35:1 depending on the model used. A recent 
international survey reported that the effective dose of present day screening CTC was 
4.4mSv(90), which is lower than used in the aforementioned study. Further dose reduction is 
possible with technical developments such as iterative reconstruction algorithms and lower 
tube voltage, leading to doses of 1 mSv(91).  
Extracolonic findings 
Extracolonic findings are common at screening CTC and have been reported to occur in one 
quarter to more than half of screenees (92-97). The incidence of extracolonic findings 
increases significantly with age; one study reported extracolonic findings in 55.4% of 
screenees younger than 65 years and 74% in those 65 years or older(96). The large majority 
of extracolonic findings are irrelevant and can be classified as such at CTC. Work up for 
(potentially) important extracolonic findings occurs in approximately 10% of cases(97-99) 
.The prevalence of extracolonic findings of moderate or high importance at CTC is 
commonly reported to be approximately 10-15% of screenees (94, 95, 98, 99), although 
higher prevalence is occasionally reported(92, 100) .This difference is partly caused by 
variation in the definition of moderately and high importance findings. The proportion of 
findings of high importance is mostly in the order of 2-5%(95, 97, 99), and includes 
approximately 0.5% extracolonic cancers, of which renal cell cancer, lung cancer and 
lymphoma are most prevalent (66, 97, 99, 100), and usually localised at the time of 
diagnosis (66). Further important extracolonic findings include abdominal aortic aneurysms, 
adrenal masses and non-malignant renal masses. The costs reported for the additional work 
up of extracolonic findings vary substantially and are influenced by the definition of a 
relevant finding needing work up and by which on-costs are included. It appears that the 
average additional costs for extracolonic findings at CTC is of the order of 25-50 USD 
averaged over all attendees (101) (94-96, 100). No studies report costs that might be saved 
by earlier detection of disease.  
 
Conclusion 
Primary CTC and colonoscopy screening have similar yields of advanced neoplasia per 
invitee. However, the impact of extracolonic findings, both medically and economically, 
remains unknown. Although radiation exposure is a drawback, this disadvantage seems to 
be over-emphasised especially given current reduction in radiation exposure of CTC. 
Probably the most important factor is the question whether CTC screening is cost-effective, 
which is still unanswered. Based on these considerations, CTC cannot be at this stage 
recommended as primary test for population CRC screening or in subjects with a first-
degree positive family history. However, it may be suggested as a CRC screening test on an 
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individual basis providing the screenees are adequately informed about test characteristics, 
benefits and risks. 
 
5. ESGE/ESGAR strongly recommend CTC in the case of positive FOBT/FIT with 
incomplete or unfeasible colonoscopy within organized population screening programs. 
(Recommendation: Strong; Evidence Level: Low). 
Repeated annual or biennial screening for colorectal cancer (CRC) by faecal occult blood 
testing (FOBT) reduces disease-specific mortality by approximately 15-18% (102). Results 
of similar repeated screening by means of faecal immunochemical testing are awaited. It is 
assumed that the impact on CRC-related mortality will be considerably higher than with 
FOBT, because of the higher uptake of FIT testing, and the higher sensitivity for advanced 
colorectal lesions (103). This is confirmed by modelling studies (104). This benefit is 
contingent on confirmation and treatment of underlying cancer or adenoma after a positive 
result. Colonoscopy combines sensitive diagnosis with therapy by endoscopic resection and 
is therefore regarded as the preferred test. Since most screenees testing FOBT/FIT positive 
will not have advanced neoplasia, CTC has been investigated as a possible triage test to 
select patients with lesions of greater size only for colonoscopy or surgery. The sensitivity of 
CTC for >6mm adenomas was above 85% in all the studies included below (15, 25, 105-
108) and over 90% for >10mm adenomas, a finding confirmed by meta-analysis published 
after our literature search(25). A modelling study concluded that the use of CTC as an 
intermediate after positive FOBT/FIT can only be cost-effective of the costs of CTC were 
<43% of the costs of colonoscopy (109). Furthermore, despite sensitivity exceeding 85%, 
lesion prevalence is so high that negative predictive value is less than might be expected, 
ranging from 85 to 95% in the studies included. These factors mean that CTC should not be 
offered routinely to those testing FOBT/FIT positive, and colonoscopy is preferable. Since 
CTC does have good diagnostic performance, it may be considered for those unwilling to 
undergo colonoscopy or in whom colonoscopy is unfeasible or incomplete, although 
screenees should be informed that sensitivity (particularly for smaller adenomas) is slightly 
inferior to colonoscopy. There is some evidence that offering CTC to those who decline 
colonoscopy increases uptake (110). CTC is safe, and therefore may be preferable in those 
with contraindications to colonoscopy or judged particularly high risk, although observational 
data suggest absolute detection rates may be lower than healthy screenees who are fit for 
colonoscopy(111). Reasons for differences in detection rates are unknown and only 
speculative at this stage. If confirmed, and if due to suboptimal CTC practice (CTC 
technique and/or image interpretation), programs for guaranteeing high quality of CTC 
exams within organized population screening programs will be necessary.  
 
6. ESGE/ESGAR recommend CT colonography with intravenous contrast medium 
injection for surveillance after resection of colorectal cancer with curative intent only in 
patients in whom colonoscopy is unfeasible (Recommendation: Weak; Evidence Level: 
Low).  
Patients with resected colorectal cancer are at a 30% risk of recurrence (112) (113) which 
can be either colonic or extracolonic. Local recurrence is less common for colonic than rectal 
cancers (112, 114, 115). Recurrence can occur either at the site of anastomosis or near the 
site of the primary resection. In contrast, metachronous lesions are colorectal adenomas and 
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cancers that develop subsequent to the index cancer and do not originate from it. 
Extracolonic recurrent disease comprises distant metastases in the liver, lung, peritoneum, 
etc.   CTC for postoperative surveillance following potentially curative resection of colorectal 
carcinoma has the potential to combine both colonic and extracolonic examination and is 
therefore an alternative to combined optical colonoscopy and contrast-enhanced abdominal 
CT (116). 
 
By means of a literature review, we identified eight cohort studies investigating contrast- 
enhanced CTC as a surveillance tool after resection of colorectal cancer (116-123). All of 
these studies demonstrated showed a high technical feasibility.  
 
Local recurrence and metachronus CRC: 
In these studies all local recurrent (n=65) and metachroneous (n=9) colonic cancers, were 
detected (116-123). The largest study included 548 patients who had subsequent 
colonoscopy and pathologic confirmation of colonic lesions (116). CTC sensitivity for 
anastomotic and metachnoneousrecurrence was 100%. Per-patient and per-lesion 
sensitivity for advanced neoplasia was 81.8% and 80.8%, and for all adenomatous lesions 
80.0% and 78.5%, respectively (116). NPV for adenocarcinoma, advanced neoplasia, and 
all adenomatous lesions were 100%, 99.1%, and 97.0%, respectively. CTC enabled 
detection of clinically unsuspected metastatic disease in 11 patients, none of them having a 
cancerous lesion in the colon (116).  
 
Adenomas / polyps: 
In a study on 548 consecutive patients without clinical or laboratory evidence of recurrence 
following curative-intent CRC who underwent contrast-enhanced CT colonography and 
subsequent colonoscopy and pathologic confirmation of colonic lesions, CTC sensitivity for 
all adenomas of 80.0% (per-patient) and 78.5% (per-lesion) have been reported in per-
patient and per-polyp analysis, respectively (116). Unfortunately, accuracy data for these 
lesions cannot be extracted from the other studies, because of the low number of patients 
with polypoid lesions, inconsistent or insufficient reporting on the detection/presence of 
polyps/adenomas and/or lack of histological polyp data impairing any stratification and 
comparison of results (117-123).  
 
 
7. ESGE/ESGAR recommend CT  colonography in patients with high-risk polyps in 
surveillance after polypectomy when colonoscopy is unfeasible (Recommendation: weak; 
Evidence Level: Low). 
The recent ESGE guidelines recommend endoscopic surveillance only for patients with high-
risk adenomatous (adenomas with villous histology or high-grade dysplasia or >10 mm in 
size, or >3 adenomas) or serrated lesions (>10 mm in size or any degree of cytological 
dysplasia) (124). Colonoscopy is considered the method of choice for post-polypectomy 
surveillance, whose primary aim is to diagnose and remove either polyps missed at initial 
examination or newly developed during the time interval between the index and follow-up 
exam. However, compliance with colonoscopic surveillance is relatively low, ranging from 
52% to 85%, with the highest levels obtained in research setting (125-128). Despite weak 
evidence supporting CTC for surveillance(15), CTC is desirable in the following scenarios: 
for patients who are unwilling or unable to undergo colonoscopy, CTC is the best alternative 
due to high sensitivity and negative predictive value, outperforming (11, 22, 29). 
 11 
 
8. ESGE/ESGAR state that CT colonography is contraindicated in patients with active 
colonic inflammation and in those who recently underwent colorectal surgery 
(Recommendation: Strong; Evidence Level: Low). 
Despite being generally regarded as safer than colonoscopy (129), CTC was shown to be 
associated with potentially serious adverse events, in particular large bowel perforation (130, 
131). Acute abdominal conditions, for example diverticulitis or active inflammatory bowel 
diseases (IBD), are absolute contraindications to CTC, because of the relatively high risk of 
complication (132) and CTC should be avoided (130). Unfortunately, there are few studies 
supporting these strong recommendations. According to a recent metanalisis(86) including 
more than 100,000 subjects, twenty-eight colonic perforations were reported. Moreover, 
eight case reports – not included in the meta-analysis – detail CTC perforation (133-140). 
These reports allow to identify some risk factors for perforation. Four (11%) out of 36 
perforated patients were affected by inflammatory bowel diseases, four patients had a 
known inguinal hernia and in one case the perforation occurred after erroneous inflation of a 
rectal stump. Moreover, mural frailty during active inflammation or in the postoperative 
setting suggests any procedure involving colonic distention entails a risk. 
 
9. ESGE/ESGAR recommend referral for endoscopic polypectomy in patients with at least 
one polyp ≥6 mm in diameter detected at CTC. CTC surveillance may be clinically 
considered if patients do not undergo polypectomy (Recommendation: Strong; Evidence 
Level: Moderate). 
Diminutive (<5 mm) polyps 
Most colorectal lesions encountered at endoscopy are polyps <5 mm (i.e. diminutive) (141). 
However, only a small proportion of these lesions meet histological criteria of advanced 
neoplasia. In detail, a recent systematic review of 408/28,947 polyps found the frequency of 
advanced neoplasia 1.4%, while the risk of invasive cancer was 0.03% (10/31,263)(142). 
Little information is available regarding the natural history of untreated <5 mm polyps. In two 
prospective Northern European endoscopic studies, Hoff et al. (143) and Hofstad et al. (144) 
followed up 194 diminutive and 253 <10 mm polyps for 3 and 2 years, respectively. No 
diminutive polyp reached >5 mm in size and only 0.5% of <10 mm polyps eclipsed the 10 
mm threshold after 1 year; no cases of severe dysplasia or carcinoma were reported(143, 
144). Similar findings were reported by a Japanese study, in which only 2.9% of 408 
subcentimetric lesions followed up for 43.1 months reached >10 mm size, without any 
invasive cancer occurring (145).  
Small (6-9 mm) polyps 
Overall, 6-9 mm (i.e. small) polyps represent about 15% of all the polyps detected during 
primary screening colonoscopy(141). In a recent systematic review of 8,605 polyps, the 
frequency of advanced neoplasia was 7.9%, while the proportion of invasive cancer was 
0.5% (41/8,456) (142). A retrospective analysis of 5,124 individuals undergoing screening 
CTC confirmed a very low risk of advanced neoplasia and invasive cancer in 464 patients 
with 6–9 mm polyps as the largest lesion, corresponding to a 3.9% and 0% risk, respectively 
(146). Recently, the natural history of 6-9 mm polyps detected at CTC was addressed by a 
longitudinal study. Specifically, 243 adults with 306 small polyps detected by CTC underwent 
a second CTC after a 2-3 year follow up (147). Overall, 22% polyps progressed, with 6% 
exceeding 10 mm. The odds ratio for a growing polyp to become an advanced adenoma 
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during surveillance was 16 compared with 6–9 mm polyps detected and removed at initial 
CTC (i.e. without surveillance). An absolute polyp volume of more than 180 mm³ at 
surveillance CTC was shown to predict advanced neoplasia (including one cancer) with a 
sensitivity of 92% (22 of 24 polyps), specificity of 94% (266 of 282 polyps), positive-
predictive value of 58% (22 of 38 polyps), and negative-predictive value of 99% (266 of 268 
polyps). Recently, factors that may predict advanced neoplasia within a subcentimeter polyp 
has been investigated. Kolligs et al. (148) applied a logistic regression model to a large, 
retrospectively-obtained cohort of 1,077,956 colonoscopies, in which 106,270 small and 
198,954 diminutive lesions were removed. The risk of advanced neoplasia within 
subcentimetric lesions was associated with increasing age, male sex, polyp morphology, 
polyp multiplicity and occult or overt blood in the stools. 
Large (>10 mm) polyps and masses 
Overall, >10 mm (i.e. large) polyps represent about 10% of all polyps detected during 
primary screening colonoscopy(141). In a previous systematic review, 73.5% (1,363/1,855) 
of these polyps appeared to be advanced adenomas, the remaining being non-adenomtous 
(141). The prevalence of invasive cancer has been recently addressed in large colonoscopic 
and CTC screening series, and ranges between 2% and 7% (146, 148, 149).  
10. ESGE/ESGAR suggest same-day polypectomy as a possible option after CTC 
performed with full bowel preparation. The implementation of this policy should take into 
account technical and logistical factors, including patient consent. (Recommendation: Weak; 
Evidence Level: Low). 
Type of laxative used for CTC 
Bowel preparation for CTC usually includes a low residue diet and clear liquids for 24 hours 
or more, and a laxative preparation that may be either a “wet prep” (e.g. polyethylene glycol, 
PEG) or “dry prep” (e.g. phosphosoda, magnesium citrate etc). In the literature search 
identifying studies employing CTC and same day colonoscopy, a range of different 
preparations were used, with approximately half using PEG, and the remaining using 
phosposoda or a similar laxative. The rationale for laxative choice was rarely stated, 
although some studies documented that choice was based on that routinely used for 
colonoscopy by the host institution. Furthermore, although data was sometimes presented 
on quality of CTC preparation, few studies formally graded bowel cleansing during same day 
colonoscopy. One large study of same day CTC and colonoscopy in 734 patients (105),  
investigated the quality of CTC imaging according to the C-RADS system and graded the 
quality of bowel preparation at colonoscopy, after preparing the patient  before CTC with  
clear liquid during the preceding 24 hours, 30 ml sodium phosphate and 20 mg bisacodyl as 
laxatives, and oral barium and iodine agents for tagging. Only 3.1% of the procedures were 
classified as inadequate for CTC interpretation, in 20 of 23 cases due to insufficient 
insufflation. At colonoscopy, colonic preparation was classified by the endoscopist as 
excellent or good in 63%, fair in 28%, poor in 8.5% and inadequate in 0.5% of patients. A 
minority of studies commented regarding the quality of preparation during colonoscopy, but 
providing little detailed information. The fact that the literature is so sparse regarding quality 
of preparation during same day colonoscopy does suggest that it is not a major issue. 
However it cannot be determined from the available literature whether one or the other 
bowel preparation is preferred for same-day colonoscopy after CTC. Although the frequency 
of and extent of retained fecal material and fluids at CTC has been extensively studied, the 
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effects on the performance of same-day colonoscopy of the various CTC preparation 
schemes is less well known.   
  
Laxative-free CTC  
Reduced bowel preparations at CTC are gaining popularity but may prevent same-day 
endoscopy (although minor fecal residue may be suctioned during OC). Our literature search 
found no information regarding the quality of same day OC after same day laxative-free 
CTC. However several studies have reported using additional bowel cleansing subsequent 
to laxative-free CTC when same day OC is required. For example, a study of 95 
symptomatic patients undergoing reduced laxative CTC used senna and 18g magnesium  
citrate, with an additional 18g of magnesium citrate after CTC but prior to OC (150).  Lefere 
et al (151) compared standard bowel preparation, reduced bowel preparation, and oral 
barium for fecal tagging in 100 patients having CTC with same day OC. In order to 
compensate for reduced bowel purgation, which may prohibit OC, PEG was administered 
after CTC, and OC performed 2-3 hours later.  
 
Fecal tagging 
Fecal tagging with oral barium or hyperosmolar/iso-osmolar iodine solutions or both is now 
considered mandatory for CTC (7). Occasionally, concern has been raised that when barium 
is used, it may interfere with the diagnostic quality of same day OC, potentially obscuring the 
endoscopic view by coating the colonic mucosa. Others have suggested that retained 
barium and iodine-based contrast agents are easily aspirated or flushed out of the way 
during endoscopy and therefore are of no concern. Our literature search, including studies of 
same-day CTC and OC with or without fecal tagging, found little specific information on this 
issue. Frequency of incomplete OC are commonly cited, indicating causes such as tortuous 
bowel, pain or strictures, but problems specifically related to fecal tagging were rarely 
mentioned. Pickhardt et al (18) analyzed 1233 asymptomatic patients undergoing CTC (with 
fecal and fluid tagging) and same-day OC with segmental unblinding. The quality of bowel 
preparation was not formally reported but only six of 1253 patients were excluded initially 
due to inadequate colonic preparation. Suboptimal colonoscopy quality was dismissed as a 
reason for missed adenomas since the OC completion rate was high at 99.4%. A similar 
tagging regime was used in another large study of same day CTC and colonoscopy in a 
population at average or high risk of colorectal cancer(105). The quality of CTC imaging was 
assessed by the radiologist according to the C-RADS system and the quality of bowel 
preparation at colonoscopy was graded by the endoscopist on a five point scale, from 
excellent to inadequate. At colonoscopy, 63% of cases were classified as excellent or good, 
28% as fair, 8.5% as poor and 0.5% as inadequate, At CTC, 23 (3.1% of the cases) cases 
were classified as C0, which includes inadequate preparation or insufflation for satisfactory 
interpretation. Twenty of the 23 cases were due to inadequate insufflation. These 23 cases 
were classified at colonoscopy as having excellent or good preparation in 65%, fair in 30%, 
and poor or inadequate in 5%. There was no mention that tagging agents were a 
complicating factor at OC.   
It can therefore be inferred indirectly from the relatively large number of comparative same-
day CTC and CC studies aimed at diagnostic accuracy, that fecal tagging likely does not 
negatively affect OC results.   
 
Logistics 
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In order for same-day endoscopy after CTC, the indications and logistics concerning patient 
selection, timing, patient transportation, availability of endoscopists and endoscopy suites 
etc. must be pre-planned jointly by radiology and endoscopy units. This paradigm also 
requires that CTC be reviewed by a radiologist immediately in order to identify patients in 
whom same day OC is needed, and in order to identify rare but well-recognised perforations 
that occur during CTC.  
 
11. ESGE/ESGAR do not recommend repetition of colonoscopy when a CTC lesion is not 
confirmed by a high-quality colonoscopy unless confidence for the presence of  a ≥10 mm 
lesion remains high following CTC re-evaluation (Recommendation: Weak; Evidence Level: 
Low). 
It is possible that colorectal lesions reported at CTC may not be detected at colonoscopy, 
either because they are CTC false-positives or colonoscopic false-negatives. Clinical 
consequences include progression of colonoscopic false-negative polyps towards invasive 
CRC or anxiety due to CTC false-positives. In a recent prospective multicentre study of 
symptomatic patients, positive predictive value of CTC for large polyps was about 60%, 
indicating that colonoscopic inability to confirm CTC findings occurs frequently (11). The 
sensitivity of colonoscopy for >10 mm polyps is higher (152), and may be presumed to be 
substantially increased when – as it occurs in daily practice – the endoscopist is searching 
specifically for a CTC finding. Therefore, the possibility of missing large lesions at such 
colonoscopies may be considered too low to warrant a further endoscopic examination. 
However, it is well-known that colonoscopy is not 100% sensitive even for large lesions that 
are present at CTC, a phenomenon that has been explained by the existence of 
colonoscopic “blind spots” (153). Most post-colonoscopic interval cancers are related to 
missed rather than new lesions. In contrast to 6-9 mm polyps, the risk of established cancer 
in larger lesions is relevant (149). Thus, if after negative colonoscopy confidence in the CTC 
diagnosis remains high, an early repetition of colonoscopy should be considered, especially 
if the abnormality appears related to flexures or on the proximal side of colonic haustra.
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